SymbolSRRK
NameSCHOLAR ROCK HOLDING CORP
SectorHEALTH CARE
RegionNorth America
IndustryBiological Products, (No Diagnostic Substances)
Address301 BINNEY STREET, CAMBRIDGE, MA 02142
Telephone857-259-3860
Fax
Email
Websitehttps://www.scholarrock.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001727196
Description

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The companys lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle.

Additional info from NASDAQ:
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The companys lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle.

2026-08-27 12:00

Scholar Rock to Present at Upcoming Investor Conferences

Read more
2026-08-21 13:06

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Read more
2026-08-14 20:15

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-08-13 12:04

New Form SCHEDULE 13G/A - Scholar Rock Holding Corp <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0002005369-26-000045 <b>Size:</b> 13 KB

Read more
2026-08-07 20:20

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Read more
2026-08-06 11:00

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Read more
2026-07-29 12:00

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Read more
2026-07-28 23:14

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

Read more
2026-07-17 20:15

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-07-06 20:30

FLIER JEFFREY S. 🔴 sold 3.1K shares of Scholar Rock Holding Corp (SRRK) at $54.88 Transaction Date: Jul 01, 2026 | Filing ID: 296252

Read more